Pfizer Inc.
DLL3 TARGETING CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS
Last updated:
Abstract:
Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.
Status:
Application
Type:
Utility
Filling date:
27 Feb 2020
Issue date:
15 Apr 2021